Evidence map›Paper›PMID 42358271›Full record

ArticleFrontiers in microbiology2026

Xuanfei Baidu decoction alleviates intestinal inflammation and modulates microbiota distribution by suppressing IMD/NF-κB and JNK signaling pathways.

Yidong Xu, Xinyi Li, Yaodong Miao, Xiaoxi Liu, Xiya Zang, Qinghao Meng, Ying Li, Fengwen Yang, Zhiguang Yuchi, Yiwen Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yidong Xu *Faculty of Medicine, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
Xinyi Li *Faculty of Medicine, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
Yaodong Miao *Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Xiaoxi Liu *First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Xiya ZangFaculty of Medicine, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
Qinghao MengFaculty of Medicine, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
Ying LiFaculty of Medicine, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
Fengwen YangState Key Laboratory for the Creation of Modern Traditional Chinese Medicine, Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Zhiguang YuchiFaculty of Medicine, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
Yiwen WangFaculty of Medicine, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Xuanfei Baidu decoction (XFBD), one of China's recommended prescriptions for COVID-19, has demonstrated clinical efficacy in mitigating gastrointestinal inflammation associated with SARS-CoV-2 infection, yet its exact therapeutic mechanism remains incompletely understood, necessitating further Methods: We induced intestinal inflammation in Results: XFBD effectively mitigated DSS-induced intestinal inflammation, leading to a significant extension of the flies' lifespan. It enhanced the integrity of intestinal barrier while reducing reactive oxygen species (ROS) levels in intestine. Additionally, XFBD restored the disrupted intestinal microbiota by regulating immune homeostasis, notably inhibiting the IMD, Toll, and JNKJAK/STAT pathways. Furthermore, the reintroduction of symbiotic microbiota partially alleviated the DSS-induced dysregulation. Conclusion: In conclusion, our study underscores the therapeutic potential of XFBD for intestinal inflammation, providing valuable insights into its key mechanisms and highlighting the pivotal role of symbiotic microbiota in anti-inflammatory responses and immune pathway regulation.

Indexed as

COVID-19intestinal floraintestinal inflammationJAK/STATJNKNF-κBXuanfei Baidu decoction

Identifiers

PMID42358271
PMCPMC13291020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.